Loading resource…

American College of Cardiology Foundation
Pulmonary hypertension (PH) associated with left heart disease (LHD) is the most prevalent form of PH and poses significant morbidity and mortality risks. Diagnosis is complicated due to overlapping phenotypes and reliance on invasive assessments. Current treatments for pulmonary arterial hypertension are ineffective and potentially harmful for this population. The review emphasizes the need for new pharmacologic and interventional therapies and discusses barriers to clinical trial design and regulatory approval.
No account needed